Kenneth Ndugga-Kabuye

Dec 12, 2023 | cellandgene.com | Kate Coleman |Kenneth Ndugga-Kabuye |Ian Burdick |Evan Hagen

Webinar: Practical Applications Of ICH E6(R3): What Do We Need To Do? Join industry experts December 14 as they discuss the strategic, conceptual, and operational implications of the shift toward risk-based monitoring in the ICH E6(R3) draft guidelines, and what sponsors and vendor partners should already be doing to thrive in the future of clinical trial management. Click here to learn more.

Sep 21, 2023 | clinicalleader.com | Kenneth Ndugga-Kabuye

Get more clinical research insight with our FREE newsletter Article | September 21, 2023 By Kenneth Ndugga-Kabuye Presently, in the United States, there exist over 10,000 rare diseases that affect in excess of 30 million individuals1. Many of these conditions pose life-threatening risks, and dishearteningly, over 90% lack an approved treatment sanctioned by the U.S. FDA2.

Sep 21, 2023 | clinicalleader.com | Kenneth Ndugga-Kabuye

By Kenneth Ndugga-Kabuye We are currently witnessing a pivotal era in clinical research within the field of gene therapies. These intricate treatments offer a beacon of hope to more than 30 million individuals in the United States who grapple with over 1000 rare diseases, many of which are life-threatening and, unfortunately, lack viable treatment options1.